FFR-CT and Stenosis under FDA review “We are standing at an inflection point in cardiovascular medicine, on the cusp of CCTA 3.0 and moving from population-based guidelines to truly personalized ...

Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to ...

BOSTON--(BUSINESS WIRE)--Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular ...

Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that its Plaque-IQ ...

Elucid's new Lesion Inspection Tool for coronary and carotid plaque analysis in its Plaque-IQ software suite provides physicians the ability to interrogate lesion-specific composition and plaque ...

BOSTON--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added ...

Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques Elucid CEO Kelly Huang, PhD, will ...

New functionality puts the power of lesion-specific plaque analysis directly into the physician’s hands, giving deeper insight into coronary and carotid artery disease Elucid announced today the ...